Additionally, we investigated the influence of the tumor process on these markers by comparing their baseline levels in plasma (VASH1, VASH2, NO) and circulating WBCs (VASH1, VASH2, iNOS) between HNSCC patients and non-cancer controls. This evidence concerns the gene VASH2 and cancer.